Literature DB >> 22763415

Genetic polymorphism of the growth arrest-specific 6 gene is associated with cutaneous vasculitis in Taiwanese patients with systemic lupus erythematosus.

Chien-Sheng Wu1, Chung-Yi Hu, Cheng-Ju Chan, Sheng-Kai Chang, Ping-Ning Hsu.   

Abstract

The growth arrest-specific 6 (GAS6) gene product participates in platelet activation and granulocyte interaction with the endothelium. Our case-control study aimed to determine whether polymorphism of GAS6 was associated with predisposing risk or specific clinical manifestations of systemic lupus erythematosus (SLE). Two of the single-nucleotide polymorphisms (SNPs) of the GAS6 gene, GAS6 834 + 7G/A (rs8191974) and GAS6 +1332C/T (rs1803628), were investigated in 83 SLE patients and 89 non-lupus control subjects. We demonstrated that among lupus patients, the GAS6 +1332 T allele was more prevalent in patients with cutaneous vasculitis (allele T 41.7 % in patients with cutaneous vasculitis compared with 18.3 % in patients without vasculitis, odds ratio (OR) 3.2, 95 % confidence interval 1.3-8.0, p = 0.016). In conclusion, GAS6 polymorphism is positively associated with cutaneous vasculitis in SLE patients, which suggests that GAS6 polymorphism could be a genetic marker for SLE with cutaneous vasculitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763415     DOI: 10.1007/s10067-012-2027-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

1.  SNPStats: a web tool for the analysis of association studies.

Authors:  Xavier Solé; Elisabet Guinó; Joan Valls; Raquel Iniesta; Víctor Moreno
Journal:  Bioinformatics       Date:  2006-05-23       Impact factor: 6.937

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients.

Authors:  Manuel Ramos-Casals; Norma Nardi; Mariana Lagrutta; Pilar Brito-Zerón; Albert Bové; German Delgado; Ricard Cervera; Miguel Ingelmo; Josep Font
Journal:  Medicine (Baltimore)       Date:  2006-03       Impact factor: 1.889

4.  Phagocytosis and clearance of apoptotic cells is mediated by MER.

Authors:  R S Scott; E J McMahon; S M Pop; E A Reap; R Caricchio; P L Cohen; H S Earp; G K Matsushima
Journal:  Nature       Date:  2001-05-10       Impact factor: 49.962

5.  TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus.

Authors:  Chang-Hee Suh; Brendan Hilliard; Sophia Li; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

6.  Gas6-mediated signaling is dependent on the engagement of its gamma-carboxyglutamic acid domain with phosphatidylserine.

Authors:  Isabelle Rajotte; Ines Hasanbasic; Mark Blostein
Journal:  Biochem Biophys Res Commun       Date:  2008-08-28       Impact factor: 3.575

7.  The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells.

Authors:  Wen-Hai Shao; Yuxuan Zhen; Robert A Eisenberg; Philip L Cohen
Journal:  Clin Immunol       Date:  2009-07-24       Impact factor: 3.969

8.  Genetic polymorphism in milk fat globule-EGF factor 8 (MFG-E8) is associated with systemic lupus erythematosus in human.

Authors:  C Y Hu; C S Wu; H F Tsai; S K Chang; W I Tsai; P N Hsu
Journal:  Lupus       Date:  2009-07       Impact factor: 2.911

9.  Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.

Authors:  Carl Ekman; Andreas Jönsen; Gunnar Sturfelt; Anders A Bengtsson; Björn Dahlbäck
Journal:  Rheumatology (Oxford)       Date:  2011-01-28       Impact factor: 7.580

10.  Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.

Authors:  Philip L Cohen; Roberto Caricchio; Valsamma Abraham; Todd D Camenisch; J Charles Jennette; Robert A S Roubey; H Shelton Earp; Glenn Matsushima; Elizabeth A Reap
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

View more
  6 in total

1.  Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis.

Authors:  Chien-Sheng Wu; Chung-Yi Hu; Hwei-Fang Tsai; I-Tsu Chyuan; Cheng-Ju Chan; Sheng-Kai Chang; Ping-Ning Hsu
Journal:  Rheumatol Int       Date:  2013-11-01       Impact factor: 2.631

2.  New evidence for roles of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus.

Authors:  Guo Tian; Jiao-Long Li; Hai-Feng Pan; Dian Zhou
Journal:  Rheumatol Int       Date:  2013-12-04       Impact factor: 2.631

Review 3.  Cutaneous vasculitis: a rheumatologist perspective.

Authors:  Trinitario Pina; Ricardo Blanco; Miguel A González-Gay
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.919

Review 4.  Contribution of Defective PS Recognition and Efferocytosis to Chronic Inflammation and Autoimmunity.

Authors:  Stanley Gititu Kimani; Ke Geng; Canan Kasikara; Sushil Kumar; Ganapathy Sriram; Yi Wu; Raymond B Birge
Journal:  Front Immunol       Date:  2014-11-10       Impact factor: 7.561

5.  Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity.

Authors:  Pedro Recarte-Pelz; Dolors Tàssies; Gerard Espinosa; Begoña Hurtado; Núria Sala; Ricard Cervera; Joan Carles Reverter; Pablo García de Frutos
Journal:  Arthritis Res Ther       Date:  2013-03-12       Impact factor: 5.156

6.  Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity.

Authors:  Gaetano Zizzo; Justus Guerrieri; Lindsay M Dittman; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.